Please use this identifier to cite or link to this item: https://hdl.handle.net/1/233
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRoger, Simon Den
dc.date.accessioned2015-04-22T23:20:29Zen
dc.date.available2015-04-22T23:20:29Zen
dc.date.issued2008-08en
dc.identifier.citationVolume 62, Issue 9, pp. 1413-1422en
dc.identifier.issn1742-1241en
dc.identifier.urihttps://elibrary.cclhd.health.nsw.gov.au/cclhdjspui/handle/1/233en
dc.description.abstractBACKGROUND: Erythropoiesis-stimulating agents (ESAs) have transformed the management of anaemia in patients with chronic kidney disease (CKD), reducing transfusion requirements and leading to improved quality of life. However, effective anaemia management with current ESAs is labour-intensive and time-consuming. Approaches are required to simplify anaemia management and reduce the burden on healthcare systems. There is increasing interest in extending the administration interval of ESAs. This would result in considerable time-savings, reducing the workload of healthcare providers and potentially reducing healthcare system costs. Time saved could be utilised in improving other aspects of patient care, such as implementation of guidelines, or treating more patients. Potential benefits of extended administration intervals for patients include a less demanding regimen and fewer injections, which could lead to improved adherence to treatment. AIM: This article reviews studies of the efficacy of current ESAs in maintaining stable haemoglobin (Hb) levels when used at extended administration intervals of up to once monthly. SUMMARY OF FINDING: Patients who are already stable on more frequent ESA therapy and who respond well to treatment may be able to maintain stable Hb with extended dosing regimens with established ESAs. However, few patients with CKD currently receive ESAs once-monthly in clinical practice. New agents with long half-lives offer the potential for extended dosing regimens in all patients with CKDen
dc.subjectAnaemiaen
dc.subjectAnemiaen
dc.subjectDrug Therapyen
dc.subjectKidney Diseaseen
dc.subjectHaematologyen
dc.subjectHematologyen
dc.titleExtended administration of Erythropoiesis-Stimulating Agents for optimising the management of Renal Anaemia: What is the evidence?en
dc.typeJournal Articleen
dc.identifier.doi10.1111/j.1742-1241.2008.01846.x.en
dc.description.pubmedurihttp://www.ncbi.nlm.nih.gov/pubmed/18793377en
dc.identifier.journaltitleInternational Journal of Clinical Practiceen
dc.originaltypeTexten
item.cerifentitytypePublications-
item.openairetypeJournal Article-
item.grantfulltextnone-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.fulltextNo Fulltext-
Appears in Collections:Renal Medicine
Show simple item record

Page view(s)

36
checked on Nov 29, 2024

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.